U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172997) titled 'Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers' on Jan. 30.
Brief Summary: The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor Metabolic dysfunction-associated steatotic liver disease (MASLD) activity and regression as a replacement for the invasive liver biopsy tool in Bahraini bariatric patients. The study also aims to identify biomarkers for predicting type 2 diabetes mellitus remission post-bariatric surgery. The main questions it aims to answer ar...